Europe In Situ Hybridization Market

Europe in Situ Hybridization Market Size (2022 to 2027)

The size of Europe in Situ Hybridization Market was worth USD 164.07 million in 2022 and estimated to be growing at a CAGR of 5.85%, to reach USD 218.01 million by 2027. The market is showcasing evident potential in the mentioned forecasting period. The market continues to gain momentum with the rapid development in the medical industry.

Factors such as the growing incidence of cancer, genetic disorders, and growing awareness of cancer diagnostic and treatment are significant drivers of Europe's in situ hybridization market growth. In addition, there is high adoption of technological advancement in the medical field coupled with well-developed healthcare infrastructure is expected to favor the market.

According to a 2020 global study, new cancer cases were accounted for 19,300,790 in 2020 worldwide, with 9,960,000 cancer deaths. The high incidence of cancers in Europe has advanced the research for FISH and CISH tests. Furthermore, the introduction of new therapeutic and diagnostics with different arrays has led to a new evolution for cancer, which has resulted in the general expansion of the market.

Additionally, in 2018, the WHO estimated that nearly 10,000 human diseases are monogenic mutations, this expands the pool for studying these varieties of disease. Thus, there is an increasing prevalence of monogenic diseases which is driving the market. Furthermore, the emerging trends in research and developing the newer product in FISH and CISH are significantly stimulating the studied market. These factors mentioned above are expected to increase the demand for in situ hybridizations in European countries during the forecast period.

According to a 2016 study conducted by the Robert Koch Institute, around 4.5 million cancer survivors developed cancer in their lifetime in Germany in 2016, including 2.8 million people who developed cancer in the past 10-year prevalence. In addition to these factors, the constant growth of the pharmaceutical and biotechnology sectors has improved the European in situ hybridization market.

Several factors, namely the strict regulatory policies, high research and development costs, availability of better technologies such as genome sequencing, microarrays, and others, are expected to hamper the growth of Europe in situ hybridization market. In addition, there is a lack of a commercial need for diagnostic procedures, a lack of reimbursement policies in some rural regions, and development in other biotechnological techniques. This is expected to negatively impact Europe in situ hybridization market during the forecast period.

This research report on Europe In situ hybridization market has been segmented and sub-segmented into the following categories.

By Technique:

• FISH
• CISH

By Application:

• Cancer Diagnosis
• Neuroscience
• Cytology
• Infectious Disease

By End User:

• Molecular Diagnostic Laboratories
• Academic and Research Institutions

By Type:

• DNA
• RNA

By Product:

• Instruments
• Probes & Kits

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the UK holds a large share of Europe's in situ hybridization market, growing at a CAGR of 5.5% during the projected period. The market growth is due to increased R&D investments by governments to promote extensive research activities, increased adoption of complementary diagnostics, positive focus in cellular biology in this region, and contributing to the overall sales of the market. During the forecast period 2022-2027, The UK will experience tremendous growth due to the increasing incidence of cancer and growing health awareness among the region's people. There are around 376,000 new cancer cases in the UK every year, or approximately 1,100 every day. In addition, there are over 182,500 new cases of cancer each year among British women, and among British men, there are around 194,000 new cases of cancer each year. The presence of these high numbers in the country will give the market an additional boost.

In Germany, it is estimated that 50% of men and 40% of women will develop cancer in their lifetime. The number of survivors has steadily increased, including patients with breast cancer and prostate cancer; these are the two most common cancers, in a context of progress and incidence among people of working age. Germany is an ever-growing market for pharmaceutical and biotechnology sectors, for many laboratories and clinical research institutes, which will positively impact the German market. Considering the above factors, Germany is expected to grow at a high CAGR in Europe's in situ hybridization market during the analysis period. Continuous research and studies on molecular cytogenetics will present significant opportunities in the region.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products are Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.).